WHO Approves a Safe, Inexpensive Typhoid Vaccine

Indian children sitting on steps happy

WHO Approves a Safe, Inexpensive Typhoid Vaccine

The company stated that as the world's first clinically proven Typbar TCV has been evaluated in Human Challenge Studies at Oxford University and typhoid conjugate vaccines have been recommended by WHO's Strategic Advisory Group of Experts on Immunization (WHO-SAGE).

Bharat, which makes vaccines against nine other diseases, including one approved by the World Health Organization for polio, is developing immunisations against Ebola, chikungunya, Zika and non-typhoid strains of Salmonella.

Should not be given to children younger than six years old.

Hyderabad-based Bharat Biotech would shortly be sending another 2,00,000 doses of its Typbar TCV vaccine to Pakistan's Hyderabad province that has been battling for the past eight months a severe drug resistant version of the disease, which killed hundreds of children.

SAGE had sought prequalification of the vaccine by World Health Organization so that TCV can be introduced in countries with the highest burden of typhoid disease or those having antibiotic resistance to Salmonella Typhi.

International Health Metrics and Evaluation (IHME) estimates that in 2016, there were approximately 12 million cases of typhoid fever resulting in around 130,000 deaths.

Intel Does Drones Again, and it's Pretty
A scaled-down version of that system now works indoors, Intel says, making it ideal for conferences, Vegas shows and bar mitzvahs. While not available for consumers, the system, designed specifically for light shows, appears to be expanding to more venues.

"For Typbar TCV to reach vulnerable populations, we are pleased to announce the price of $ 1.50/ dose for procurement for GAVI supported countries".

Laboratory workers who work with Salmonella Typhi bacteria.

Typhoid disproportionately impacts children and adolescents, disrupting a child's education and affecting families' and communities' economic development and potential. Most typhoid cases in the U.S. are from people who have recently traveled internationally.

The Sabin Vaccine Institute, which serves as the secretariat of the Coalition against Typhoid, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. Bharat Biotech is appreciative to Dr. John Robbins, who in 1999 trusted the team to deliver the promise of vaccines against typhoid fever. Together, the Coalition and TyVAC are working to focus attention on typhoid and the need for typhoid conjugate vaccines, and improved water, sanitation, and hygiene interventions to reduce the burden and impact of typhoid fever.

"With the recent Gavi Board approval of $85 million funding window to make the typhoid conjugate vaccine available in Gavi-supported countries, we now expect the first introductions to take place as soon as the first half of 2019", Seth Berkley, CEO of Gavi, the Vaccine Alliance, said.

Latest News